Vectus Biosystems Limited (AU:VBS)
ASX:VBS
Want to see AU:VBS full AI Analyst Report?
VBS Stock Chart & Stats
AU$0.18
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.18
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.04 - AU$0.46
Previous CloseN/A
Volume32.26K
Average Volume (3M)97.35K
Market Cap
AU$8.30M
Enterprise ValueAU$8.15M
Total Cash (Recent Filing)AU$330.50K
Total Debt (Recent Filing)AU$467.10K
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding61,494,150
10 Day Avg. Volume169,215
30 Day Avg. Volume97,349
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-8.29
Price to Sales (P/S)4.45
P/FCF Ratio-2.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginsA consistently high gross margin indicates the company’s core therapeutic products and delivery platforms can generate strong unit economics. Over the medium term this provides a clear path to scalable profitability once operating spend is controlled or revenue from licensing ramps, limiting marginal cost pressure on future growth.
Niche Fibrosis/hypertension Focus & IPA focused therapeutic strategy targeting fibrosis and hypertension, combined with an IP/licensing commercialization model, supports durable competitive advantage. Specialization in high-unmet-need indications can attract partners and milestone revenue, enabling capital-efficient scaling and risk-sharing with pharma collaborators over months to years.
Modest Absolute DebtModest nominal debt reduces immediate interest and covenant pressure, preserving short-term solvency flexibility. Given negative equity elsewhere, low debt levels still matter: they give management runway to secure partnerships or equity raises without imminent debt servicing strain, supporting operational continuity in the medium term.
Bears Say
Sharp Revenue DeclineA 45.9% revenue drop materially weakens operating leverage and suggests diminishing commercial traction or partner payments. Persistently shrinking top-line reduces runway and increases reliance on external financing or milestone deals, delaying break-even and constraining the company’s ability to fund R&D without dilutive capital.
Persistent Cash BurnOperating and free cash flow have been deeply negative and track net losses roughly 1x, meaning losses translate into real cash outflows. This structural cash burn pressures liquidity, forces frequent financing, and restricts sustained R&D investment or commercialization unless partnerships or funding are secured, raising execution risk.
Negative Shareholders' EquityNegative equity materially reduces financial flexibility and can deter lenders and partners. It distorts leverage metrics, elevates solvency concerns, and raises the likelihood of dilutive equity raises or onerous financing terms. Structurally this limits the company’s capacity to absorb setbacks and execute long-term development plans.
Vectus Biosystems Limited News
VBS FAQ
What was Vectus Biosystems Limited’s price range in the past 12 months?
Vectus Biosystems Limited lowest share price was AU$0.04 and its highest was AU$0.46 in the past 12 months.
What is Vectus Biosystems Limited’s market cap?
Vectus Biosystems Limited’s market cap is AU$8.30M.
When is Vectus Biosystems Limited’s upcoming earnings report date?
Vectus Biosystems Limited’s upcoming earnings report date is Sep 02, 2026 which is in 71 days.
How were Vectus Biosystems Limited’s earnings last quarter?
Vectus Biosystems Limited released its earnings results on Feb 26, 2026. The company reported -AU$0.014 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.014.
Is Vectus Biosystems Limited overvalued?
According to Wall Street analysts Vectus Biosystems Limited’s price is currently Overvalued.
Does Vectus Biosystems Limited pay dividends?
Vectus Biosystems Limited does not currently pay dividends.
What is Vectus Biosystems Limited’s EPS estimate?
Vectus Biosystems Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vectus Biosystems Limited have?
Vectus Biosystems Limited has 61,494,150 shares outstanding.
What happened to Vectus Biosystems Limited’s price movement after its last earnings report?
Vectus Biosystems Limited reported an EPS of -AU$0.014 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.571%.
Which hedge fund is a major shareholder of Vectus Biosystems Limited?
Currently, no hedge funds are holding shares in AU:VBS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vectus Biosystems Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
143.75%
12-Months-Change
Fundamentals
Return on Equity
265.12%
Trailing 12-Months
Asset Growth
-62.59%
Trailing 12-Months
Company Description
Vectus Biosystems Limited
Vectus Biosystems Limited, an Australian medical research and development firm, specializes in devising therapies for fibrotic conditions and hypertension. Its pharmaceutical pipeline addresses ailments affecting the heart, kidneys, liver, and lungs. The company's leading experimental drug, VB0004, aims to counter the degradation of functional tissue resulting from fibrosis, scarring, and elevated blood pressure. Furthermore, Vectus intends to advance treatments for hepatic fibrotic diseases, such as non-alcoholic steatohepatitis, and various pulmonary fibrotic disorders. Beyond its therapeutic endeavors, the company also provides AccuCal and RealCount software, tools engineered to enhance the swiftness and precision of DNA and RNA quantification in laboratory settings. Established in 2005, Vectus Biosystems is headquartered in Rosebery, Australia.